First Page | Document Content | |
---|---|---|
![]() Date: 2013-08-08 09:56:46Cytokines Cancer research Nitriles Organofluorides CCL2 LNCaP Prostate cancer MDV3100 STAT3 Biology Medicine Cell lines | Add to Reading List |
![]() | Award ID: CP130020 Project Title: Androgen Receptor N-Terminus Blocker Program for Prostate Cancer Award Mechanism: Company RelocationDocID: 19pfm - View Document |
![]() | 5.5 ENZALUTAMIDE, capsule, 40 mg, Xtandi®, Astellas Pharma Australia Pty Ltd, Purpose of Application Authority required (Streamlined) listing for enzalutamide for treatment of metastatic prostate cancer after treatmentDocID: 17GTi - View Document |
![]() | PDF DocumentDocID: 16Qjm - View Document |
![]() | Microsoft PowerPoint - Figure MQ[removed]DocID: ZzdJ - View Document |
![]() | Queensland Prostate Cancer News This magazine is a publication of the Queensland Chapter, Prostate Cancer Foundation of Australia. Letter from the EditorDocID: YHLd - View Document |